Harrow
NASDAQ · HROW·Nashville, TN·Small-cap·Approved
Specialty ophthalmic pharma operating an integrated commercial portfolio of branded and proprietary eye-care products in the U.S. Branded portfolio includes VEVYE for dry eye, IHEEZO for ocular surface anesthesia, Triesence intravitreal triamcinolone, and IMPRIMIS-style compounded ophthalmics. 2026 guidance: $350–365M revenue, $80–100M adjusted EBITDA.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Harrow Corporate Presentation — March 2026 | Corporate overview | March 15, 2026 | 32 |